Posted from: Monday, February 01, 2016 - 01:41 PM - Present

Gleostine Approved with New Strength

January 6, 2016 – The U.S. Food and Drug Administration (FDA) approved Gleostine (lomustine) 5mg capsules, manufactured by NextSource Biotechnology. Gleostine is indicated for treating brain cancer as well as for second-line therapy in combination with other drugs for patients with Hodgkin’s disease who relapse or fail to respond to other treatments. Gleostine already comes in 10mg, 40mg and 100mg capsules. With dosing at 130mg per meter squared (m2) of body surface area, patients often need capsules in different strengths to get the exact dose they need.  Gleostine is to be taken once every six weeks.

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

Last Updated Sunday, October 15, 2017 - 12:47 PM.